CA2262066C - Methode rapide pour determiner la clairance des proteines prions - Google Patents

Methode rapide pour determiner la clairance des proteines prions Download PDF

Info

Publication number: CA2262066C
Authority: CA; Canada
Prior art keywords: sample; western blot; protein; tse; proteinase
Prior art date: 1999-02-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA 2262066

Other languages

English (en)

Other versions

CA2262066A1 (fr

Inventor

Steve R. Petteway

Douglas C. Lee

Robert W. Kozak

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bayer Healthcare LLC

Original Assignee

Bayer Healthcare LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-22

Filing date

1999-02-22

Publication date

2006-06-06

1999-02-22 Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC

1999-02-22 Priority to CA 2262066 priority Critical patent/CA2262066C/fr

2000-08-22 Publication of CA2262066A1 publication Critical patent/CA2262066A1/fr

2006-06-06 Application granted granted Critical

2006-06-06 Publication of CA2262066C publication Critical patent/CA2262066C/fr

2019-02-22 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims description 68
102000029797 Prion Human genes 0.000 title abstract description 15
108091000054 Prion Proteins 0.000 title abstract description 15
238000001262 western blot Methods 0.000 claims abstract description 70
102000004169 proteins and genes Human genes 0.000 claims abstract description 67
108090000623 proteins and genes Proteins 0.000 claims abstract description 67
238000003018 immunoassay Methods 0.000 claims abstract description 26
208000024777 Prion disease Diseases 0.000 claims description 59
239000000523 sample Substances 0.000 claims description 56
239000012528 membrane Substances 0.000 claims description 37
238000010790 dilution Methods 0.000 claims description 31
239000012895 dilution Substances 0.000 claims description 31
208000010544 human prion disease Diseases 0.000 claims description 29
108010067770 Endopeptidase K Proteins 0.000 claims description 28
238000001514 detection method Methods 0.000 claims description 21
238000012545 processing Methods 0.000 claims description 21
210000004556 brain Anatomy 0.000 claims description 16
239000000872 buffer Substances 0.000 claims description 14
239000000243 solution Substances 0.000 claims description 8
239000003656 tris buffered saline Substances 0.000 claims description 7
238000005119 centrifugation Methods 0.000 claims description 5
208000008864 scrapie Diseases 0.000 claims description 5
238000012421 spiking Methods 0.000 claims description 5
125000006853 reporter group Chemical group 0.000 claims description 4
150000003839 salts Chemical class 0.000 claims description 4
239000002981 blocking agent Substances 0.000 claims description 3
239000012470 diluted sample Substances 0.000 claims description 3
238000007865 diluting Methods 0.000 claims description 3
238000005406 washing Methods 0.000 claims description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
239000007975 buffered saline Substances 0.000 claims 4
238000001914 filtration Methods 0.000 claims 2
230000001717 pathogenic effect Effects 0.000 abstract description 19
238000004166 bioassay Methods 0.000 abstract description 13
238000004519 manufacturing process Methods 0.000 abstract description 10
235000018102 proteins Nutrition 0.000 description 42
210000002381 plasma Anatomy 0.000 description 35
238000003556 assay Methods 0.000 description 27
102100025818 Major prion protein Human genes 0.000 description 15
101710138751 Major prion protein Proteins 0.000 description 15
239000000047 product Substances 0.000 description 14
238000000638 solvent extraction Methods 0.000 description 9
238000002965 ELISA Methods 0.000 description 8
241000699800 Cricetinae Species 0.000 description 7
241000283984 Rodentia Species 0.000 description 7
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
239000000463 material Substances 0.000 description 7
239000002953 phosphate buffered saline Substances 0.000 description 7
238000005194 fractionation Methods 0.000 description 6
239000000499 gel Substances 0.000 description 6
244000052769 pathogen Species 0.000 description 6
230000035945 sensitivity Effects 0.000 description 6
238000012546 transfer Methods 0.000 description 6
238000004458 analytical method Methods 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
239000003085 diluting agent Substances 0.000 description 5
239000003550 marker Substances 0.000 description 5
239000008188 pellet Substances 0.000 description 5
241000282414 Homo sapiens Species 0.000 description 4
241000700605 Viruses Species 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
239000003814 drug Substances 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
239000007787 solid Substances 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
239000000020 Nitrocellulose Substances 0.000 description 3
108091005804 Peptidases Proteins 0.000 description 3
102000035195 Peptidases Human genes 0.000 description 3
239000012472 biological sample Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
229920001220 nitrocellulos Polymers 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
235000019833 protease Nutrition 0.000 description 3
238000001742 protein purification Methods 0.000 description 3
238000000746 purification Methods 0.000 description 3
239000012723 sample buffer Substances 0.000 description 3
108010088751 Albumins Proteins 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 2
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
239000006180 TBST buffer Substances 0.000 description 2
239000010836 blood and blood product Substances 0.000 description 2
238000010261 blood fractionation Methods 0.000 description 2
229940125691 blood product Drugs 0.000 description 2
210000005013 brain tissue Anatomy 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000009826 distribution Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
235000013861 fat-free Nutrition 0.000 description 2
238000000703 high-speed centrifugation Methods 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
238000002955 isolation Methods 0.000 description 2
230000005541 medical transmission Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000012800 visualization Methods 0.000 description 2
102100034452 Alternative prion protein Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
238000000665 Cohn process Methods 0.000 description 1
208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
208000035976 Developmental Disabilities Diseases 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
241000257303 Hymenoptera Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
238000007792 addition Methods 0.000 description 1
238000013019 agitation Methods 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000012131 assay buffer Substances 0.000 description 1
238000002820 assay format Methods 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000004568 cement Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000003113 dilution method Methods 0.000 description 1
UKWLRLAKGMZXJC-QIECWBMSSA-L disodium;[4-chloro-3-[(3r,5s)-1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl]phenyl] phosphate Chemical compound [Na+].[Na+].O1OC2([C@@H]3CC4C[C@H]2CC(Cl)(C4)C3)C1(OC)C1=CC(OP([O-])([O-])=O)=CC=C1Cl UKWLRLAKGMZXJC-QIECWBMSSA-L 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
238000005259 measurement Methods 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
235000008476 powdered milk Nutrition 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
239000012474 protein marker Substances 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000005070 sampling Methods 0.000 description 1
229940016590 sarkosyl Drugs 0.000 description 1
108700004121 sarkosyl Proteins 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
238000011895 specific detection Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
238000007794 visualization technique Methods 0.000 description 1
239000012224 working solution Substances 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Investigating Or Analysing Biological Materials (AREA)
Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

CA 2262066 1999-02-22 1999-02-22 Methode rapide pour determiner la clairance des proteines prions Expired - Lifetime CA2262066C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA 2262066 CA2262066C (fr)	1999-02-22	1999-02-22	Methode rapide pour determiner la clairance des proteines prions

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 2262066 CA2262066C (fr)	1999-02-22	1999-02-22	Methode rapide pour determiner la clairance des proteines prions

Publications (2)

Publication Number	Publication Date
CA2262066A1 CA2262066A1 (fr)	2000-08-22
CA2262066C true CA2262066C (fr)	2006-06-06

Family

ID=29555160

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2262066 Expired - Lifetime CA2262066C (fr)	1999-02-22	1999-02-22	Methode rapide pour determiner la clairance des proteines prions

Country Status (1)

Country	Link
CA (1)	CA2262066C (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1596199A1 (fr) *	2004-05-14	2005-11-16	Prionics AG	Méthode de détection des formes pathogènes des protéines prions.
CN118745237B (zh) *	2024-06-04	2025-09-23	沧州市天津工业大学研究院	一种辣根过氧化物酶介导的表面引发制备表面印迹聚合物微球的方法及其应用

1999
- 1999-02-22 CA CA 2262066 patent/CA2262066C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2262066A1 (fr)	2000-08-22

Legal Events

Date	Code	Title	Description
2002-09-09	EEER	Examination request
2019-04-28	MKEX	Expiry	Effective date: 20190222

Publication	Publication Date	Title
Lee et al.	2000	Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein
EP0891553B1 (fr)	2002-06-19	Methode de detection des encephalopathies spongiformes transmissibles
HUP0104890A2 (hu)	2002-04-29	Eljárás és készlet prion protein extrahálására
CA1146067A (fr)	1983-05-10	Methode de dosage immunologique en phase solide utilisant un anticorps anti-haptene marque
Barnard et al.	2000	The measurement of prion protein in bovine brain tissue using differential extraction and DELFIA® as a diagnostic test for BSE
Simon et al.	2008	The identification of disease-induced biomarkers in the urine of BSE infected cattle
US7504204B2 (en)	2009-03-17	Detection of transmissible spongiform encephalopathy (TSE) protein employing a highly sensitive Western blot assay and chemiluminescent detection system
CA2262066C (fr)	2006-06-06	Methode rapide pour determiner la clairance des proteines prions
US20020137114A1 (en)	2002-09-26	Method of detecting PrP protein and kits therefor
Lukan et al.	2013	TSE diagnostics: recent advances in immunoassaying prions
Nunnally	2002	It's a mad, mad, mad, mad cow: a review of analytical methodology for detecting BSE/TSE
AU2005246032B2 (en)	2010-08-12	Method for the detection of disease-related prion
Soutyrine et al.	2017	A novel approach for scrapie-associated prion (PrPSc) detection in blood using the competitive affinity of an aggregate-specific antibody and streptavidin to PrPSc
US20050089943A1 (en)	2005-04-28	Rapid method of determining clearance of prion protein
US7713515B2 (en)	2010-05-11	Methods and compositions for use in diagnosing and characterizing diseases involving abnormal apoptosis
Dabaghian et al.	2006	An immunoassay for the pathological form of the prion protein based on denaturation and time resolved fluorometry
Sandholm	2019	Development and evaluation of immunoassays for complement diagnostics
Benjamin et al.	1980	Evaluation of solid-phase immunofluorescence for quantitation of antibodies to herpes simplex virus and cytomegalovirus
Barnard et al.	2003	The diagnosis of transmissible spongiform encephalopathies using differential extraction and DELFIA
Lee	1989	An enzyme immunoassay for urinary albumin at low concentrations
Missler et al.	1995	Time-resolved immunofluorometric assay for the quantification of lipoprotein (a) in serum
Sachse et al.	2003	Role of variant Creutzfeldt‐Jakob disease for safety of treatment with blood components: screening of lymphatic tissue is a potential tool for risk assessment
Gilbert et al.	2003	Detection of residual donor leucocytes in leucoreduced red blood cell components using a fluorescence microplate assay
Sy	2003	The Diagnosis of Transmissible Spongiform Encephalopathies Using Differential
Alpert	2003	Mary Jo Schmerr